High-risk HPV test in cervical cancer prevention – present and future

Despite the introduction of HPV vaccines and its clinical application expanded during the last decade with increasing vaccine coverage, cervical cancer prevention still requires continuing and widespread screening activity. Based on the knowledge about the impact of HPV on cell cycle control mechanisms, tests for detection of HPV DNA, host cellular proteins or HPV proteins have been developed and introduced to clinical application. Among them, tests able to detect DNA of high-risk HPVs have been widely used worldwide and start to be evidenced as a valuable screening test in cervical cancer prevention. Hybrid Capture II (HCII, Qiagen, USA) using DNA hybridization and signals amplification technique is the FDA and EC approved test, which can detect and differentiated any type from 13 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and 5 low-risk HPV types (6, 11, 42, 43, 44). The introduction of a newly developed HPV test using simpler technology and affordable cost - careHPV - and its commercialization in the very near future, in combination with visual inspection with acetic acid and/or colposcopy will allow the implementation of new approaches with higher coverage and a more effective strategy of screening – diagnosis – management.

Download Full-text

Use of Fast Transfer Analysis Cartridges for Cervical Sampling and Real Time PCR Based High Risk HPV Testing in Cervical Cancer Prevention - a Feasibility Study from South India

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2015.16.14.5993 ◽

2015 ◽

Vol 16 (14) ◽

pp. 5993-5999

Author(s):

Ramshankar Vijayalakshmi ◽

Thangaraj Soundara Viveka ◽

JS Malliga ◽

Kothandaraman Murugan ◽

Albert Kanchana ◽

...

Keyword(s):

Cervical Cancer ◽

High Risk ◽

Cancer Prevention ◽

Real Time ◽

Feasibility Study ◽

Real Time Pcr ◽

South India ◽

Cervical Cancer Prevention ◽

Hpv Testing ◽

High Risk Hpv

Download Full-text

Cervical Human Papillomavirus Prevalence, Genotypes, and Associated Risk Factors among Female Sex Workers in Greater Accra, Ghana

Journal of Oncology ◽

10.1155/2019/8062176 ◽

2019 ◽

Vol 2019 ◽

pp. 1-7 ◽

Cited By ~ 2

Author(s):

Abdul Rashid Adams ◽

Priscillia Awo Nortey ◽

Benjamin Ansah Dortey ◽

Richard Harry Asmah ◽

Edwin Kwame Wiredu

Keyword(s):

Cervical Cancer ◽

High Risk ◽

Cancer Prevention ◽

Sex Workers ◽

Female Sex Workers ◽

Cervical Cancer Prevention ◽

Human Papillomaviruses ◽

Female Sex ◽

Hpv Prevalence ◽

Hpv Genotypes

Cervical cancer is a largely preventable disease mediated by persistent infection with high-risk Human Papillomaviruses (Hr-HPV). There are now three approved vaccines against the most common HPV genotypes. In Ghana, mortality due to cervical cancer is on the rise, due to the absence of an organized and effective cervical cancer prevention and control program. Data on circulating HPV genotypes is important for studying the likely impact of mass introduction of HPV vaccination of the female population before sexual debut. High HPV prevalence has been reported in Female Sex Workers (FSWs), who constitute an important active group for maintenance of HPV in the population. This study was conducted to determine the size of HPV prevalence in this group and to provide information for future assessment of the impact of vaccine introduction in the country. We conducted a cross-sectional study where the snowballing technique was used to identify and select FSW’s ≥18 years, operating within suburbs of Greater Accra Region (GAR). A risk factor assessment interview was conducted and cervical swabs were collected for HPV-DNA detection and genotyping by Nested Multiplex PCR. Hundred participants, age ranging from 18 to 45 years, median 24 years, were studied. The prevalence of Cervical HPV was 26%. Eleven genotypes were detected comprising 9 high-risk in order of decreasing prevalence HPV-16 (8%), HPV-35 (5%), HPV-33/39/-68 (3%), HPV-52/51/59 (2%) and HPV-18 (1%) and 2 Low-risk types, HPV-42(3%), and HPV-43 (1%). Three women had HPV types that could not be genotyped by our method. Oral contraceptives use was associated with a reduced chance of HPV infection (P=0.002; OR=0.19, 95% CI 0.07-0.54). This study found a high HPV prevalence among FSWs in the GAR. A high number of Hr-HPV genotypes seen are vaccine preventable, providing additional compelling argument for implementing a national cervical cancer prevention plan including vaccination.

Download Full-text

Development of a direct education workshop for cervical cancer prevention in high risk women: The Forsyth County project

Journal of Cancer Education ◽

10.1080/08858199009528072 ◽

1990 ◽

Vol 5 (4) ◽

pp. 217-223 ◽

Cited By ~ 7

Author(s):

Mark Dignan ◽

Pheon Beal ◽

Robert Michielutte ◽

Penny Sharp ◽

L. Ann Daniels ◽

...

Keyword(s):

Cervical Cancer ◽

High Risk ◽

Cancer Prevention ◽

Cervical Cancer Prevention ◽

High Risk Women ◽

Education Workshop ◽

Forsyth County

Download Full-text

Evaluation of the SureX HPV Genotyping Test for the Detection of High-Risk HPV in Cervical Cancer Screening

10.21203/rs.3.rs-32573/v1 ◽

2020 ◽

Author(s):

Baojun Wei ◽

Ping Mei ◽

Shengkai Huang ◽

Xueting Yu ◽

Tong Zhi ◽

...

Keyword(s):

Cervical Cancer ◽

Cancer Screening ◽

High Risk ◽

Cervical Cancer Screening ◽

Cervical Intraepithelial Neoplasia Grade ◽

Agreement Rate ◽

Hpv Genotyping ◽

Hpv Test ◽

Hpv Types ◽

High Risk Hpv

Abstract Background: The SureX HPV genotyping test (SureX HPV test), which targets the human papillomavirus (HPV) E6/E7 genes was compared with the Cobas 4800 and Venus HPV tests for detecting 14 high-risk HPV (HR-HPV) types in clinical referral and follow-up patients to evaluate its value for cervical cancer screening.Methods: Two different populations were enrolled in the study. The first population comprised 185 cases and was used for comparing the SureX HPV test (Health, China) with the Cobas 4800 test (Roche, USA). The second population comprised 290 cases and was used for comparing the SureX HPV test (Health, China) with the Venus HPV test (Zhijiang, China). Polymerase chain reaction (PCR) sequencing was performed for further confirmation of discordant results.Results: In the first population, the overall agreement rate was 95.3% for 14 High-Risk HPV types. Eight discordant cases were confirmed by PCR sequencing, which showed that the agreement rates were 75.0% between the SureX HPV test and PCR sequencing and 25.0% between the Cobas 4800 test and PCR sequencing (P<0.01). In the second population, the overall agreement rate was 94.5%. Thirteen discordant cases were confirmed by PCR sequencing, which showed that the agreement rates were 76.9% between the SureX HPV test and PCR sequencing and 23.1% between the Venus HPV test and PCR sequencing (P<0.01). With cervical intraepithelial neoplasia grade 2+ (CIN2+) as the reference standard, the sensitivity values of the SureX HPV test and the Venus HPV test were 93.5% and 92.0%, (P>0.05), while the specificity values were 43.3% and 46.7%, respectively (P>0.05).Conclusion: The SureX HPV test had good consistency with both the Cobas 4800 and Venus HPV tests for 14 HR-HPV types. In addition, it avoided some false negatives and false positives. Therefore, the SureX HPV test can be used for cervical cancer screening.

Download Full-text